Sixal Inc
Biotech · Private
LARI E59, a monoclonal antibody therapeutic for prevention of severe IgE-mediated food allergic reactions and mastocytosis
- Grants
- $3.3M
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 6
- 2 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Targeting surface-bound IgE as a novel allergy therapeutic | $749,892 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Targeting surface-bound IgE as a novel allergy therapeutic | $1,489,545 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeting surface-bound IgE as a novel allergy therapeutic | $739,653 | |
| Federal grant | Department of Health and Human Services · Phase I · Safety and efficacy of an allergy therapeutic targeting FcERI bound IgE in human immune reconstituted mice. | $286,656 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3134 | Engrail Therapeutics | — | — |
| 3135 | PHAGEPRO, INC. | — | — |
| 3136 | HTIC, INC. | — | — |
| 3137 | Sixal Inc | — | — |
| 3138 | Nirogyone Therapeutics LLC | — | — |
| 3139 | SEAK Therapeutics, LLC | — | — |
| 3140 | ALCAMENA STEM CELL THERAPEUTICS, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Therapeutic Anti-IgE Antibodies and Methods and Compositions Thereofapplication
- Therapeutic Anti-IgE Antibodies and Methods and Compositions Thereofgranted
- Anti-Immunoglobulin E Antibodies and Methods of Using Thereofgranted
- Therapeutic Anti-ige Antibodies And Methods And Compositions Thereofapplication
- Therapeutic Anti-IgE Antibodies and Methods and Compositions Thereofapplication
- Anti-immunoglobulin E Antibodies And Methods Of Use Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.